We examined cerebral spinal fluid (CSF) from multiple sclerosis (MS) Patien
ts and patients with other neurological diseases (OND) for antibody specifi
c for Human Herpesvirus-6 (HHV-6) and for HHV-6 DNA detectable by PCR CSF f
rom MS patients had a higher frequency of IgG antibody to HHV-6 late antige
ns (39.4%) compared with CSF from OND (74%). In contrast, the frequency of
detectable IgG antibody in CSF from MS patients specific for Epstein-Barr V
irus (EBV) (12.1%) and Human Cytomegalovirus (HCMV) (6.1%) was much lower.
Two of 12 MS CSFs (16.7%) also contained HHV-6 DNA detected by PCR None of
four OND CSF were positive for HHV-6 DNA. Plasma from 16 patients with MS,
eight with OND and 72 healthy donors were tested for antibodies by ELISA to
HHV-6 early (p41/38) and late (gp110) proteins. Although no differences in
anti-gp110 IgG antibody were detected between MS patients, patients with o
ther neurological diseases, and normals IgG antibody to early protein p41/3
8 was detected in >68% of the plasma from MS patients 12.5% from OND patien
ts and 27.8% of the controls IgM antibody to p41/38 was present in >56% of
MS patients, 12.5% of OND patients, and 19% of controls These data suggest
that more than half of the MS patients had active, ongoing HHV-6 infections
. HHV-6 was also isolated from peripheral blood mononuclear cells (PBMC) fr
om 3/5 MS patients who were in relapse or had progressive disease and was i
dentified as HHV-6 Variant B. These preliminary results support the hypothe
sis that HHV-6 may be a co-foctor in the pathogenesis of some cases of MS.